Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SHANGHAI PECHEM
00338
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (FY)Dec 31, 2022 | (FY)Dec 31, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | 17.58%1.99B | 23.24%918.66M | 39.76%1.69B | --745.4M | 70.65%1.21B | --708.67M | ---- | ---- |
| Operating income | 17.58%1.99B | 23.24%918.66M | 39.76%1.69B | 745.4M | 70.65%1.21B | 708.67M | ||
| Cost of sales | -24.30%-1.79B | -31.23%-824.31M | -42.17%-1.44B | ---628.14M | -68.09%-1.01B | ---602.17M | ---- | ---- |
| Operating expenses | -24.30%-1.79B | -31.23%-824.31M | -42.17%-1.44B | -628.14M | -68.09%-1.01B | -602.17M | ||
| Gross profit | -20.90%198.55M | -19.53%94.36M | 27.34%251M | 117.25M | 85.08%197.1M | 106.49M | ||
| Selling expenses | -9.46%-15.2M | -24.33%-9.81M | -21.02%-13.89M | ---7.89M | -47.52%-11.47M | ---7.78M | ---- | ---- |
| Administrative expenses | 38.93%-70.03M | 24.31%-36.3M | -88.28%-114.68M | ---47.96M | -122.41%-60.91M | -33,297.56%-27.39M | 62.73%-82K | ---220K |
| Research and development expenses | 23.17%-24.79M | 39.48%-10.58M | 3.19%-32.27M | ---17.49M | -59.95%-33.33M | ---20.84M | ---- | ---- |
| Impairment and provision | -53.16%-22.23M | 182.24%4.38M | -477.22%-14.52M | ---5.32M | -1.04%-2.52M | ---2.49M | ---- | ---- |
| -Other impairment is provision | -53.16%-22.23M | 182.24%4.38M | -477.22%-14.52M | ---5.32M | -1.04%-2.52M | ---2.49M | ---- | ---- |
| Operating interest expense | ---- | ---- | ---- | ---- | ---- | ---11.04M | ---- | ---- |
| Special items of operating profit | -162.06%-7.82M | 8.52%4.34M | 465.31%12.6M | --4M | -45.39%2.23M | 172.39%4.08M | -80,614.29%-5.64M | --7K |
| Operating profit | -33.73%58.48M | 8.89%46.38M | -3.14%88.25M | 42.59M | 121.99%91.11M | 817.77%41.04M | -2,584.51%-5.72M | -213K |
| Financing cost | -184.68%-63.29M | -360.57%-26.57M | -112.70%-22.23M | ---5.77M | ---10.45M | ---- | ---- | ---- |
| Share of profits of associates | ---- | ---- | ---- | ---- | 48.56%-232K | -105.15%-451K | 373.22%8.76M | --1.85M |
| Share of profit from joint venture company | 45,918.18%5.06M | ---97K | --11K | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | -99.62%252K | -46.46%19.71M | -17.90%66.03M | 36.82M | 98.13%80.42M | 1,232.60%40.59M | 85.85%3.05M | 1.64M |
| Tax | 34.55%-12.41M | 94.01%-411K | -72.02%-18.96M | ---6.87M | -156.36%-11.02M | ---4.3M | ---- | ---- |
| After-tax profit from continuing operations | -125.83%-12.16M | -35.57%19.3M | -32.18%47.07M | 29.96M | 91.23%69.4M | 1,091.46%36.29M | 85.85%3.05M | 1.64M |
| Earning after tax | -125.83%-12.16M | -35.57%19.3M | -32.18%47.07M | 29.96M | 91.23%69.4M | 1,091.46%36.29M | 85.85%3.05M | 1.64M |
| Profit attributable to shareholders | -125.83%-12.16M | -35.57%19.3M | -32.18%47.07M | 29.96M | 91.23%69.4M | 1,091.46%36.29M | 85.85%3.05M | 1.64M |
| Basic earnings per share | -125.00%-0.03 | -50.00%0.04 | -40.00%0.12 | 0.08 | -99.87%0.2 | 434.73%159.03 | 81.45%29.74 | 16.39 |
| Diluted earnings per share | -127.27%-0.03 | -50.00%0.04 | 0.11 | 0.08 | 434.73%159.03 | 81.45%29.74 | 16.39 | |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion | Unqualified Opinion |
| Auditor | -- | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.